Teleflex's Stock Buy Rating: Diverse Portfolio and Strategic Market Advantages Propel Growth
Teleflex Analyst Ratings
RBC Capital Maintains Teleflex(TFX.US) With Buy Rating, Maintains Target Price $260
RBC Capital Remains a Buy on Teleflex (TFX)
Truist Financial Maintains Teleflex(TFX.US) With Hold Rating, Announces Target Price $247
Teleflex Price Target Raised to $260.00/Share From $235.00 by RBC Capital
Teleflex Analyst Ratings
BofA Securities Maintains Teleflex(TFX.US) With Hold Rating
Needham Maintains Teleflex(TFX.US) With Hold Rating
A Quick Look at Today's Ratings for Teleflex(TFX.US), With a Forecast Between $243 to $290
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX) and Teleflex (TFX)
Teleflex Holds Steady: Solid Performance With Moderate Growth Outlook Despite Headwinds
Buy Rating Affirmed for Teleflex on Strong Performance and Promising Outlook
Wells Fargo Raises Teleflex's Price Target to $243 From $210
Teleflex Poised for Growth: Strong Q2 Performance and Strategic Initiatives Validate Buy Rating
Teleflex's Barrigel Poised for Growth in Prostate Therapy Market, Yet Holds Steady Amid Balanced Expectations
Teleflex Analyst Ratings
Truist Raises Price Target on Teleflex to $240 From $235, Maintains Hold Rating
Teleflex Analyst Ratings
Piper Upgrades Teleflex to Overweight, Cites Expected EPS Growth